Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCANDIUM II: IHP + Ipilimumab/Nivolumab in Uveal Melanoma
NCT04463368Phase 1Completed
- Sponsor
- Region Västra Götaland
- Start
- Mar 2021
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ipilimumab and nivolumab in Uveal melanoma (UM) (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Incidence and severity of adverse events and serious adverse events at 1 year. Started Mar 2021; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT04463368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04463368.